Phacetoperane - NLS Pharmaceutics Ltd
Alternative Names: NLS-3; PhacetoperaneLatest Information Update: 11 Oct 2023
At a glance
- Originator NeuroLifeSciences
- Developer NLS Pharma; NLS Pharmaceutics Ltd
- Class Acetates; Anorectics; Antidepressants; Behavioural disorder therapies; Esters; Piperidines; Small molecules
- Mechanism of Action Central nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pervasive child development disorders
- Discontinued Attention-deficit hyperactivity disorder; Narcolepsy
Most Recent Events
- 09 Oct 2023 Discontinued - Phase-I for Attention-deficit hyperactivity disorder in Switzerland (unspecified route) before October 2023 (NLS Pharmaceutics pipeline, October 2023)
- 09 Oct 2023 Preclinical trials in Pervasive child development disorders in Switzerland (unspecified route) before October 2023 (NLS Pharmaceutics pipeline, October 2023)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder in Switzerland